Why digitalization is vital to combating the challenges of Russia's pharma market

10 August 2018

“The Russian pharma market is like a huge ocean. If you know who lives in the ocean and what sort of currents the ocean has, then it is all simple and understandable.”

Those words were spoken by Elena Vatutina, chief executive and founder of Pharmznanie, a company that specializes in market access to the Russian pharma market by using digital technologies.

Opportunities clearly exist for drugmakers in Russia given that the market is one of the fastest-growing globally, in monetary terms. GlobalData predicted last year that it would rise by a compound annual growth rate of 13% to $38.56 billion by 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK